Document is current
Any future updates will be listed below
-
Authors
Lapointe, Julie
Guillaumie, Laurence
Dionne, Anne
Lalonde, Lyne
Lemieux, Julie
Dorval, Michel
Nabi, Hermann
Lemay, Martine
Guénette, Line
Guertin, Jason Robert
Mâsse, Benoît
Lauzier, Sophie
-
Funding
Funding for this research was provided by:
Institute of Cancer Research (420809)
Fondation du cancer du sein du Québec (4323)
Fonds de Recherche du Québec - Santé
- License Information
-
More Information
Article History
Received: 8 April 2024
Accepted: 16 June 2025
First Online: 14 July 2025
Declarations
:
: This study has been approved by the Research Ethics Board of the CHU de Québec-Université Laval (MP-20–2023-6625) and registered at Clinicaltrials.gov (NCT05887102) on 2023–05-24, prior to beginning the study. The electronic consent forms included the study’s preamble, objectives, eligibility criteria, data collection, and follow-up procedures, a summary explanation of the intervention, the potential risks and benefits involved, voluntary participation and right of withdrawal, monetary compensation (for pharmacists supporting recruitment efforts), information on confidentiality and anonymized data sharing, and identification of contact persons. A copy of the signed informed consent was sent by email to participants and kept in a secured access server.
: Not applicable.
: The authors declare that they have no competing interests.
